It’s never good news when a drug firm posts an “update” about a phase 3 trial, and Bristol-Myers Squibb’s PR team have had to issue news of another trial disappointment from the misfiring c
Celgene has scored a major regulatory win ahead of its proposed merger with Bristol-Myers Squibb, with the FDA backing its rare bone marrow cancer drug Inrebic.
